 |
| Image Source: The Hindu |
Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik V- the world’s first registered vaccine against coronavirus.
The single-dose Sputnik Light vaccine
demonstrated 79.4% efficacy according to analyzed data taken from 28 days after
the injection was administered as part of Russia’s mass vaccination program
between 5 single-dose20 and 15 April 2021.
An efficacy level of almost 80% is higher
than that of many two-dose vaccines.
Sputnik Light has proven effective against
all new strains of coronavirus, as demonstrated by the Gamaleya Center during
laboratory tests.
Phase I/II of the Safety and Immunogenicity
Study of the Sputnik Light vaccine has demonstrated that:
- Sputnik Light can elicit the development of antigen-specific lgG antibodies in 96.9% of individuals on the 28th day after vaccination
- The Sputnik Light vaccine elicits the development of virus-neutralizing antibodies in 91.67% of individuals on the 28th-day post-immunization
- Cellular immune response against the S Protein of SARS-CoV-2 develops in 100% of volunteers on the 10th day
- The immunization of individuals with pre-existing immunity against SARS-CoV 2 with Sputnik Light can elicit the increase of the level of antigen-specific IgG antibodies by more than 40x in 100% of subjects 10 days after immunization
- No serious adverse events were
registered after vaccination with Sputnik Light
As of May 5, 2021, more than 20 million
people globally have received their first shot of Sputnik V.
Sputnik Light is compatible with standard
vaccine storage and logistics requirements, while also being affordable with a
price of less than $10. The single-dose regimen allows for the immunization of
a larger number of people in a shorter time frame, furthering the fight against
the pandemic during the acute phase.
The Sputnik Light vaccine is based on a
well-studied human adenoviral vector platform that has proven to be safe and
effective, with no long-term side effects, as confirmed in over 250 clinical
trials conducted globally over the past two decades (while the history of use
of human adenoviruses in vaccine development started in 1953).
The two-dose Sputnik V vaccine remains the
main vaccination tool. Moscow, May 6,
2021 – The Russian Ministry of Health, the Gamaleya National Research Center of
Epidemiology and Microbiology, and the Russian Direct Investment Fund (RDIF,
Russia's sovereign wealth fund) announce that Sputnik Light, a single dose
COVID-19 vaccine has received authorization for use in Russia.
Sputnik Light is the first component
(recombinant human adenovirus serotype number 26 (rAd26)) of the Sputnik V coronavirus
vaccine.
The single-dose Sputnik Light vaccine demonstrated 79.4% efficacy according to analyzed data taken from 28 days after the injection was administered. An efficacy level of near 80% is higher than that of many two-dose vaccines.
The efficacy rate was calculated based on
data obtained from Russians vaccinated with a single injection, having not
received the second one for any reason during the mass vaccination program between
December 5, 2020, and April 15, 2021.
The infection rate among vaccinated
subjects from the 28th day from the date of the injection was only 0.277%. Over
the same period, the infection rate among the unvaccinated adult population was
1.349%.
Phase I/II Safety and Immunogenicity Study
of the single-dose Sputnik Light vaccine was initiated in January 2021, and the
interim results were received on March 10, 2021:
 |
| Image Source: News18 |
The results demonstrated that the vaccine
can elicit the development of antigen-specific IgG antibodies in 96.9% of
volunteers on the 28th day after immunization;
- Virus-neutralizing antibodies developed in 91.67% of volunteers on the 28th-day post-immunization
- Cellular immune response against the S Protein of SARS-CoV-2 developed in 100% of volunteers
- No serious adverse events were registered after vaccination with Sputnik Light
- The immunization of individuals
with pre-existing immunity against SARS-CoV 2 with Sputnik Light can elicit an
increase of the level of IgG antibodies by more than 40x in 100% of volunteers
on the 10th day after immunization
As of May 5, 2021, more than 20 million
people globally have received the first injection of the Sputnik V vaccine,
containing the first component. There have been no cases of Cerebral Venous
Sinus Thrombosis (CVST) reported. The production of the vaccine meets the
strictest standards, with four stages of purification (two chromatographic
stages and two stages of tangential filtration).
The Sputnik Light vaccine is based on a well-studied human adenoviral vector platform that has proven to be safe and effective.
Written By - Violet Priscilla S
Edited By - Anamika Malik
Social